BioNTech on track for worst day since March after ending colorectal cancer trial

Roche Holding AG

28/08/2026 17:46

Updates
** U.S.-listed shares of German drugmaker BioNTech BNTX.O 22UAy.DE fall 7.4% to $103.07, putting the stock on course for its worst day since March if losses hold
** Shares of fellow mRNA drugmaker Moderna MRNA.O fall 4.3% to $136.68 
** Co terminates mid-stage trial of its experimental personalized mRNA treatment autogene cevumeran in patients with high-risk colorectal cancer who had undergone surgery
** The trial failure prompted some brokerages to lower their price targets on BioNTech's stock
** Says independent monitors found a numerical imbalance in overall survival between patients receiving the treatment and those under watchful waiting, and concluded that continuing the trial was unlikely to change the outcome
** Does not disclose which group had worse survival, but says no new safety concerns were found
** Says a separate trial testing the treatment with other cancer medicines in pancreatic cancer will continue as planned; treatment is being jointly developed with Roche's ROPC.S Genentech unit
** Including session's moves, BNTX up ~8% YTD 

(Reporting by Kunal Das and Sahil Pandey in Bengaluru)
((Kunal.Das2@thomsonreuters.com;))